MENU
+Compare
GMAB
Stock ticker: NASDAQ
AS OF
Oct 17 closing price
Price
$33.17
Change
+$0.42 (+1.28%)
Capitalization
20.48B

GMAB Genmab A/S ADS Forecast, Technical & Fundamental Analysis

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer... Show more

GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GMAB with price predictions
Oct 16, 2025

GMAB sees MACD Histogram just turned negative

GMAB saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for GMAB moved out of overbought territory on October 09, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where GMAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GMAB broke above its upper Bollinger Band on September 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in of 332 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 224 cases where GMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.851) is normal, around the industry mean (24.455). P/E Ratio (17.158) is within average values for comparable stocks, (54.854). Projected Growth (PEG Ratio) (1.118) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (6.447) is also within normal values, averaging (352.090).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GMAB is expected to report earnings to fall 13.36% to 46 cents per share on November 06

Genmab A/S ADS GMAB Stock Earnings Reports
Q3'25
Est.
$0.47
Q2'25
Beat
by $0.15
Q1'25
Beat
by $0.09
Q4'24
Beat
by $0.49
Q3'24
Missed
by $0.02
The last earnings report on August 07 showed earnings per share of 54 cents, beating the estimate of 38 cents. With 1.99M shares outstanding, the current market capitalization sits at 20.48B.
A.I. Advisor
published General Information

General Information

an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Carl Jacobsens Vej 30
Phone
+45 70202728
Employees
2204
Web
https://www.genmab.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IYG86.840.65
+0.75%
iShares US Financial Services ETF
XBJA31.290.12
+0.37%
Innovator US Eq Acclrtd 9 Bffr ETF Jan
SMAP24.76N/A
N/A
Amplify Small-Mid Cap Equity ETF
ARKA68.32N/A
N/A
ARK 21Shares Active Bitcoin Futures Strategy ETF
PDN40.90-0.02
-0.05%
Invesco RAFI Developed Mkts ex-US S-METF

GMAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
+0.09%
GNMSF - GMAB
58%
Loosely correlated
+0.03%
AXON - GMAB
47%
Loosely correlated
+1.11%
TECH - GMAB
40%
Loosely correlated
+3.39%
ARGX - GMAB
38%
Loosely correlated
+2.66%
ARVN - GMAB
37%
Loosely correlated
+2.33%
More